Miguel Forte, Bone Therapeutics CEO
March 29, 2022 07:36 AM EDT
People

In a twist, cell ther­a­py de­vel­op­er sees C-suite ex­o­dus while slash­ing costs

Amber Tong

We’ve seen the same scene plen­ty of times over re­cent months: A trou­bled biotech, usu­al­ly a mi­cro­cap, let­ting go of a por­tion of its em­ploy­ees …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times